JacobLalezariMD

Internal Medicine • San Francisco, CA

Physician

Join to view full profile

Dr. Lalezari is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lalezari's full profile

Already have an account?

Office
2300 Sutter St
San Francisco, CA 94115
Phone+1 415-353-0800

Fax+1 415-353-0801

Education & Training

University of California (San Francisco)/Mount ZionResidency, Internal Medicine, 1986 - 1989
Perelman School of Medicine at the University of PennsylvaniaClass of 1986

Certifications & Licensure

CA State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine

Clinical Trials

Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive Start of enrollment: 2006 Oct 01
Terminated
Phase 1
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days Start of enrollment: 2008 Nov 01
Completed
Phase 2
Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients Start of enrollment: 2007 Apr 01
Completed
Phase 1
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection Start of enrollment: 2013 Apr 01
Completed
Phase 1, Phase 2
Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C) Start of enrollment: 2013 May 10
Completed
Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine Start of enrollment: 2014 Jul 01
Completed
Phase 2
Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection Start of enrollment: 2014 Apr 16
Completed
Phase 2
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV Start of enrollment: 2015 Aug 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

100 citations
Phase I Dose Escalation Trial Evaluating the Pharmacokinetics, Anti-Human Cytomegalovirus (HCMV) Activity, and Safety of 1263W94 in Human Immunodeficiency Virus-Infect...
Jacob Lalezari, Judith A. Aberg, Laurene H. Wang, Mary Beth Wire, R C Miner
Antimicrobial Agents and Chemotherapy. 2002-09-01
209 citations
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group
Stephen A. Spector, George McKinley, Jacob Lalezari, Tobias Samo, Robert Andruczk
The New England Journal of Medicine. 1996-06-06
492 citations
All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
David R. Nelson, James N. Cooper, Jacob Lalezari, Eric Lawitz, Paul J. Pockros
Hepatology. 2015-04-01

Press Mentions

Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 Days on ECMO; Case Study Published in Journal of Translational AutoimmunityMarch 29th, 2021
CytoDyn to Hold Webcast on October 20 to Discuss DSMC's Recommendations from the Interim Analysis of the Phase 2b/3 Clinical Trial for Severe-to-Critical COVID-19 PatientsOctober 17th, 2020
CytoDyn to Hold Conference Call on September 16 to Provide Update on Discussions with FDA and MHRA for COVID-19 and FDA Meeting on BLA FilingSeptember 10th, 2020
Join now to see all